Axogen, Inc. — Third Quarter 2026 Earnings Summary

Axogen, Inc. reported third-quarter 2026 revenue of $75.8 million, representing a 26.2% increase from the prior year, and raised its full-year revenue guidance to at least $290 million. The company completed the acquisition of BioCircuit Technologies on October 1, 2026, and closed a public offering that generated $225 million in net proceeds to fund the transaction. Adjusted net income for the quarter reached $13.1 million, or $0.21 per share, while cash and investments increased to $350.1 million by the end of the period. Commercial payer coverage for the company's Avance product now extends to approximately 96% of covered lives in the United States following positive decisions from major insurers.